Illumina, Inc. (ILMN)

Market Cap	15.53B
Revenue (ttm)	4.28B
Net Income (ttm)	1.26B
Shares Out	153.77M
EPS (ttm)	7.91
PE Ratio	12.77
Forward PE	21.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,269,382
Open	102.16
Previous Close	102.12
Day's Range	100.56 - 102.68
52-Week Range	68.70 - 156.66
Beta	1.40
Analysts	Buy
Price Target	124.00 (+22.75%)
Earnings Date	Nov 3, 2025

About ILMN

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 28, 2000
• Employees: 10,370
• Stock Exchange: NASDAQ
• Ticker Symbol: ILMN
• Website: https://www.illumina.com

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Analyst Summary

According to 15 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price target is $124.0, which is an increase of 22.75% from the latest price.

Price Target

$124.0

(22.75% upside)

Analyst Consensus: Buy